A novel trial evaluated the impact of Levagen+® Palmitoylethanolamide (PEA) supplementation on cognitive function and BDNF levels in healthy adults. Over a 6-week period, participants received either PEA or a placebo in a double-blinded crossover study.
A novel trial evaluated the impact of Levagen+® Palmitoylethanolamide (PEA) supplementation on cognitive function and BDNF levels in healthy adults. Over a 6-week period, participants received either PEA or a placebo in a double-blinded crossover study. Results indicated a significant rise in serum BDNF levels post-PEA supplementation compared to placebo, alongside enhanced memory performance demonstrated by improved first success and reduced errors on cognitive tests. This study marks the first to demonstrate the cognitive benefits of Levagen+® PEA, suggesting its potential as a valuable intervention for cognitive enhancement, supported by elevated levels of the neurotrophic marker BDNF
Source : https://pubmed.ncbi.nlm.nih.gov/38398813/